Navigation Links
Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens
Date:8/1/2011

NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

http://www.reportlinker.com/p0581172/Sustained-Release-Injectables-Evolving-Formulations-Improving-Dosing-Regimens .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

The ability to formulate injectable drugs to increase the duration of efficacy for a given dose and simultaneously reduce the dosing frequency addresses several important health care issues. Less frequent dosing is believed to improve patient safety, reduce the incidence of injection site complications and improve compliance with drug protocols. Sustained release formulations mitigate the bolus effect at the time of injection, and thus have a salutary influence on drug side effects. All of these advantages, along with the need for fewer patient caregiver visits (for practitioner-administered drugs) have a positive, downward impact on overall healthcare costs. Currently approved sustained release injectables rely on a spectrum of branded formulation technologies to modulate the drug's release profile post-injection. Typically off-patent or generic drugs, they include drug therapies for almost a dozen major therapeutic segments, including neurological conditions, metabolic diseases, oncology, pain management and reproductive health. As the incidence and prevalence of chronic illnesses increases with the aging population, the attraction and interest in sustained release injectables will increase.

Highlights

• Provides detailed analysis of sustained release injectable products, market segments, market dynamics and market demographics

• Analyzes therapeutic demand drivers and evaluates commercial sustained release injectables in eleven major therapeutic segments

• Charts sustained release product data and market share, and provides forecasts to 2015

• Profiles sustained release technology participants, their product development activities, business strategies, and corporate alliances and affiliations

Executive Summary

Injectable Drug Market Dynamics

The Trend toward Self-Administration

Shifting Demographics

Injectable Drug Formulation Technology

Innovation in Injectable Device Designs

Therapeutic Demand Drivers

Competitive Landscape

Risk Factors

Sustained Release Injectables - Branded Formulation Technologies

Biodegradable Polymers

PEG

PLG/PLA/PLGA

Polyether ester

Other Polymers

ChroniJect

CriticalMix

Depofoam

LinkeRx

Liposomes

Medisorb

Medusa

Optisomes

OxtoDEX

SABER/SAIB

Sucrose acetate isobutyrate

SynBiosys

Supercritical Fluid

Analysis of FDA Approved Sustained Release Injectables

cytarabine

goserelin acetate

Interferon

lanreotide acetate

leuprolide acetate

morphine

naltrexone

olanzapine

octreotide acetate

risperidone

paliperidone palmitate

somatostatin

triptorelin pamoate

Development-Stage SR Injectable Drug Candidate Assessment

Addiction

Antivirals

Hormones

Immune Modulators

Incretin Mimetics

Local Anesthetics

Opioid Antagonists

Psychotropics

Antineoplastics

SR Injectables – Therapeutic Sector Impact Analysis & Forecasts

Addiction

Autoimmune Diseases

Diabetes

Infectious Disease

Macular Degeneration

Metabolic Diseases

Neurology

Oncology

Pain Management

Reproductive Health

Sustained Release Injectables – Company Profiles

To order this report:

Drug and Medication Industry: Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens

Drug and Medication Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
2. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
3. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
4. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
5. CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
6. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
7. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
8. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
9. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
10. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
11. Spherics, Inc. Offers Extended Release Formulation for Sustained and Stable Levodopa Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... January 18, 2017 , , Marks E-QURE ... distribution agreement, following similar agreements in Israel ... Wound care is $2 5 billion ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of ... Médica Equipos Médicos S.A.S. (TeckMedica) in Colombia for the ...
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
(Date:1/18/2017)... PAUL, Minn. , Jan. 18, 2017 /PRNewswire-USNewswire/ ... developer of medical devices using neuroblocking technology to ... today announced the pricing of an underwritten public ... million, prior to deducting underwriting discounts and commissions ... The offering is comprised of Class A Units, ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 19, 2017 , ... Aerolib Healthcare Solutions ... Clinical and Regulatory education for Physicians, Physician Advisors, Case managers, Utilization Review ... of Disease Specific Documentation Improvement. , The Aerolib Learning Management System is ...
(Date:1/19/2017)... ... 19, 2017 , ... LabRoots , the leading provider ... world, announces the launch of its newly redesigned website. The sleek new design ... and trending news, vital information on upcoming virtual events and webinars, all while ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... Gattefossé, the leader in innovative excipients and drug delivery solutions to health industries ...
(Date:1/19/2017)... ... ... Students interested in video can get a jump start on their education ... $1,000 scholarship and have his or her video posted on the GenCure website and ... with the winner announced on June 9. , The competition is designed to help ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sam & Associates ... to commercial and residential clients in the California Bay Area, is launching a charity ... in the region. , Heart disease is the primary killer of adult men and ...
Breaking Medicine News(10 mins):